Product Images Levetiracetam

This is a prescription medication information for Levetiracetam tablets, containing 1000 mg of the active ingredient. It provides guidance on storage conditions, dosage, and dispensing instructions for pharmacists. The medication guides can be accessed online, and the tablets should be kept out of reach of children. The manufacturer is Granules India Limited, and the medication is manufactured for Granules Pharmaceuticals Inc.*

This is a prescription drug information for Levetiracetam tablets, USP, containing 250 mg per film-coated tablet. It includes details for pharmacists on dispensing the medication guide to each patient, dosage recommendations, storage instructions, and safety measures for keeping the drug out of the reach of children. The medication is manufactured by Granules India Limited for Granules Pharmaceuticals Inc.*

This text provides information on Levetiracetam tablets, USP. It includes details such as the dosage strength (500 mg), proper storage conditions, prescription instructions, and manufacturer information. It also emphasizes the importance of keeping the medication out of the reach of children and dispensing it in a secure container. The medication guide should be provided to each patient along with the prescription.*

This is a description of a medication containing 750 mg of Levetiracetam. It is a film-coated tablet with specific dosage instructions provided on the package insert. The pharmacist is instructed to dispense it in a tight, light-resistant container with a child-resistant closure. Storage recommendations include keeping it at 20° to 25°C (68° to 77°F). The medication guide should be provided to each patient separately. This tablet is manufactured for Granules Pharmaceuticals Inc.*

This is a graphical representation showing the Responder Rate with a 250% Reduction from Baseline in Study 1. The chart displays percentages ranging from 0% to 39.6%. A comparison is made with different treatments, denoting statistical significance versus placebo.*

This is a description of the responder rate (250% reduction from baseline) in Study 2, during Period A. The text also mentions percentages related to different groups of patients and the comparison between the treatment groups. The study involves the use of Levetiracetam (1000 mg/day and 2000 mg/day) and a placebo. It indicates a statistically significant difference between the treatment with Levetiracetam and the placebo.*

This text provides data on the Responder Rate (≥50% Reduction from Baseline) in Study 3, comparing the placebo group (N=104) to the Levetiracetam 3000 mg/day group (N=180). The response rates are illustrated in a table ranging from 0% to 45%. The Levetiracetam group had a response rate that was statistically significant compared to the placebo group.*

This text provides information on the Responder Rate (= 50% Reduction from Baseline) in Study 4. The Responder Rate for Placebo was 5%, while for Levetiracetam it was 19.6%. It is noted that Levetiracetam was statistically significant compared to Placebo in this study.*

This text provides information on the responder rate for all patients aged between 1 month to under 4 years, showing a greater than 50% reduction from baseline in Study 5. The data includes the percentage values for placebo and levetiracetam groups, and indicates that the levetiracetam group had a statistically significant difference compared to the placebo group.*

This is a visualization of the Responder Rate (250% Reduction from Baseline) in Primary Generalized Tonic-Clonic (PGTC) Seizure Frequency per Week in Study 7. The graph compares the percentage of responders between the placebo group (N=84) and the group taking tiracetam (N=79). It is noted that the response to tiracetam was statistically significant compared to the placebo.*